简体
简体中文
繁體中文

Grupo Aval Acciones y Valores SA AVAL

已收盘 12-19 16:00:00 美东时间

4.10

+0.050

+1.23%

华盛通华盛通
立即下载
  • 最 高4.30
  • 今 开4.09
  • 成交量 10.25万股
  • 最 低 4.00
  • 昨 收 4.05
  • 总市值 48.67亿
  • 52周最高 4.50
  • 市盈率 5.19
  • 换手率 0.01%
  • 52周最低 2.00
  • 委 比 33.33%
  • 总股本 11.87亿
  • 历史最高 9.2437
  • 量 比 1.37
  • 振 幅 7.41%
  • 历史最低 0.7658
  • 每 手 1
  • 风险率 0.58%

个股概要

财务分析

公司资料

相关新闻

分红派息

  • 分时图
  • 日k
  • 周k
  • 月k

相关新闻

更多
  • 车展速递|高山7亮相 魏牌将推下一代全动力智能超级平台

    被长城汽车董事长魏建军预告许久的魏牌高山7,终于亮相8月29日开幕的2025成都国际车展。据悉,高山7将于9月中旬开启预售。 从目前魏牌对外释放的信息来看,高山...

    08-29 21:19

  • 哈弗大狗2026款上市 限时权益价9.89万元起

    近日,哈弗大狗2026款正式上市,新车共推出3款车型,售价区间为12.39万元-14.99万元,限时权益价9.89万元-12.49万元。 作为年度改款...

    07-21 10:10

  • Avadel Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

    Avadel Pharmaceuticals announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2025. A live webcast and archived recording will be available on the company's Investor Relations website for 90 days. The company focuses on innovative solutions for medications, with its product LUMRYZ™ approved for narcolepsy treatment. Investor and media contacts are provided.

    05-29 12:00

  • Avalo Therapeutics to Participate in Upcoming Investor Conferences

    Avalo Therapeutics announced that its management will participate in two investor conferences in June: the Jefferies Global Healthcare Conference on June 4 and the Oppenheimer Innovators in I&I Summit on June 25. The company focuses on treating immune dysregulation, with its lead asset being AVTX-009, an anti-IL-1β monoclonal antibody targeting inflammatory diseases.

    05-27 14:05